Abstract As the major nonpsychotropic constituent of Cannabis sativa, cannabidiol (CBD) is regarded as one of the most promising therapeutic agents due to its proven effectiveness in clinical trials for…
Condition: Multiple Sclerosis
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
Abstract Background This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently…
The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms
Abstract Multiple sclerosis (MS) is known as an autoimmune disease that damages the neurons in the central nervous system. MS is characterized by its most common symptoms of spasticity, muscle…
Botanically-Derived Δ9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis
Abstract The innate immune response to bacterial and viral molecules involves the coordinated production of cytokines, chemokines, and type I interferons (IFNs), which is orchestrated by toll-like receptors (TLRs). TLRs,…
Evaluation of different phytochemicals from Cannabis sativa against Myelin oligodendrocyte glycoprotein receptor
Abstract There is a rapid spread of multiple sclerosis (MS) disorder across the globe. There are around 2.8 million cases of Multiple Sclerosis in the world; among them, 1 million are…
Therapeutic use of medical Cannabis in neurological diseases: a clinical update
Abstract The use of medical Cannabis has increased in recent years due to changing legal circumstances in many countries. Approval exists only for a few neurological conditions such as rare forms of…
Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study
Please use this link to access this publication: https://www.sciencedirect.com/science/article/abs/pii/S0303846720303334?via%3Dihub Abstract Objective: Moderate to severe spasticity is commonly reported in Multiple Sclerosis (MS) and its management is still a challenge. Cannabinoids were recently…
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Please follow this link to access the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30032-8/fulltext Abstract In the past two decades, there has been an increasing interest in the therapeutic potential of cannabinoids for neurological disorders…
The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis
Abstract Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS…